Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
81% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. PGNX: No Debt )
PGNX' s 10-Year Cash to Debt Range
Min: 65   Max: No Debt
Current: No Debt

Equity to Asset 0.79
PGNX's Equity to Asset is ranked higher than
82% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PGNX: 0.79 )
PGNX' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.98
Current: 0.79

0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
65% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
PGNX' s 10-Year Interest Coverage Range
Min: 2   Max: 9999.99
Current: No Debt

2
9999.99
F-Score: 6
Z-Score: 5.95
M-Score: 14.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 15.45
PGNX's Operating margin (%) is ranked higher than
91% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. PGNX: 15.45 )
PGNX' s 10-Year Operating margin (%) Range
Min: -878.82   Max: 35.29
Current: 15.45

-878.82
35.29
Net-margin (%) 16.78
PGNX's Net-margin (%) is ranked higher than
92% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. PGNX: 16.78 )
PGNX' s 10-Year Net-margin (%) Range
Min: -876.82   Max: 33.33
Current: 16.78

-876.82
33.33
ROE (%) 7.91
PGNX's ROE (%) is ranked higher than
91% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. PGNX: 7.91 )
PGNX' s 10-Year ROE (%) Range
Min: -95.77   Max: 45.13
Current: 7.91

-95.77
45.13
ROA (%) 5.89
PGNX's ROA (%) is ranked higher than
91% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. PGNX: 5.89 )
PGNX' s 10-Year ROA (%) Range
Min: -79.08   Max: 38.93
Current: 5.89

-79.08
38.93
ROC (Joel Greenblatt) (%) 75.14
PGNX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. PGNX: 75.14 )
PGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1616.79   Max: 1542.86
Current: 75.14

-1616.79
1542.86
Revenue Growth (%) -16.40
PGNX's Revenue Growth (%) is ranked higher than
68% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. PGNX: -16.40 )
PGNX' s 10-Year Revenue Growth (%) Range
Min: -55.7   Max: 71
Current: -16.4

-55.7
71
EBITDA Growth (%) -28.60
PGNX's EBITDA Growth (%) is ranked higher than
60% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. PGNX: -28.60 )
PGNX' s 10-Year EBITDA Growth (%) Range
Min: -28.6   Max: 51.4
Current: -28.6

-28.6
51.4
EPS Growth (%) -29.20
PGNX's EPS Growth (%) is ranked higher than
62% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. PGNX: -29.20 )
PGNX' s 10-Year EPS Growth (%) Range
Min: -73.5   Max: 221.4
Current: -29.2

-73.5
221.4
» PGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PGNX Guru Trades in Q4 2013

Louis Moore Bacon 95,000 sh (+90%)
Paul Tudor Jones 2,342,795 sh (+0.02%)
Murray Stahl 67,200 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q1 2014

PGNX Guru Trades in Q1 2014

Steven Cohen 28,878 sh (New)
Murray Stahl 67,200 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones 2,342,388 sh (-0.02%)
» More
Q2 2014

PGNX Guru Trades in Q2 2014

Paul Tudor Jones 2,342,388 sh (unchged)
Murray Stahl 67,200 sh (unchged)
» More
Q3 2014

PGNX Guru Trades in Q3 2014

Julian Robertson 1,290,055 sh (New)
Chuck Royce 680,000 sh (New)
Paul Tudor Jones 2,356,092 sh (+0.59%)
Murray Stahl 67,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2014-09-30 New Buy1.8%$4.15 - $5.56 $ 7.2345%1290055
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 144.60
PGNX's P/E(ttm) is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PGNX: 144.60 )
PGNX' s 10-Year P/E(ttm) Range
Min: 12.88   Max: 169.27
Current: 144.6

12.88
169.27
P/B 3.70
PGNX's P/B is ranked higher than
81% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. PGNX: 3.70 )
PGNX' s 10-Year P/B Range
Min: 1.08   Max: 16.48
Current: 3.7

1.08
16.48
P/S 10.80
PGNX's P/S is ranked higher than
83% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. PGNX: 10.80 )
PGNX' s 10-Year P/S Range
Min: 1.92   Max: 62.55
Current: 10.8

1.92
62.55
EV-to-EBIT 56.14
PGNX's EV-to-EBIT is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PGNX: 56.14 )
PGNX' s 10-Year EV-to-EBIT Range
Min: -50.8   Max: 72
Current: 56.14

-50.8
72
Current Ratio 21.30
PGNX's Current Ratio is ranked higher than
96% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PGNX: 21.30 )
PGNX' s 10-Year Current Ratio Range
Min: 2.67   Max: 32.92
Current: 21.3

2.67
32.92
Quick Ratio 21.30
PGNX's Quick Ratio is ranked higher than
96% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. PGNX: 21.30 )
PGNX' s 10-Year Quick Ratio Range
Min: 2.67   Max: 32.92
Current: 21.3

2.67
32.92

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.80
PGNX's Price/Net Cash is ranked higher than
83% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. PGNX: 9.80 )
PGNX' s 10-Year Price/Net Cash Range
Min: 1.59   Max: 22.41
Current: 9.8

1.59
22.41
Price/Net Current Asset Value 6.10
PGNX's Price/Net Current Asset Value is ranked higher than
87% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. PGNX: 6.10 )
PGNX' s 10-Year Price/Net Current Asset Value Range
Min: 1.54   Max: 21.55
Current: 6.1

1.54
21.55
Price/Tangible Book 5.20
PGNX's Price/Tangible Book is ranked higher than
81% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. PGNX: 5.20 )
PGNX' s 10-Year Price/Tangible Book Range
Min: 1.22   Max: 13.73
Current: 5.2

1.22
13.73
Price/Median PS Value 1.00
PGNX's Price/Median PS Value is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. PGNX: 1.00 )
PGNX' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.33
Current: 1

0.21
5.33
Price/Graham Number 3.80
PGNX's Price/Graham Number is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PGNX: 3.80 )
PGNX' s 10-Year Price/Graham Number Range
Min: 2   Max: 12.08
Current: 3.8

2
12.08
Earnings Yield (Greenblatt) 1.80
PGNX's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. PGNX: 1.80 )
PGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 10.2
Current: 1.8

1.4
10.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PGP.Germany
Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidates are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase 2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 26 2013 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 

More From Our Partners
Are Central Banks Panicking? Nov 21 2014 - SEEKINGALPHA

More From Other Websites
Nasdaq stocks posting largest percentage increases Nov 26 2014
Progenics (PGNX) Shares March Higher, Can It Continue? Nov 17 2014
PROGENICS PHARMACEUTICALS INC Financials Nov 15 2014
Tiger Management's Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, ... Nov 14 2014
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 12 2014
Progenics Pharmaceuticals to Participate in Upcoming Conferences Nov 11 2014
Progenics Pharmaceuticals to Participate in Upcoming Conferences Nov 11 2014
Progenics Pharmaceutical (PGNX) Upgraded From Sell to Hold Nov 11 2014
10-Q for Progenics Pharmaceuticals, Inc. Nov 09 2014
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 07 2014
Progenics Pharmaceuticals Announces Third Quarter 2014 Financial Results Nov 07 2014
Progenics posts 3Q profit Nov 07 2014
Progenics posts 3Q profit Nov 07 2014
Progenics Pharmaceuticals Announces Third Quarter 2014 Financial Results Nov 07 2014
Q3 2014 Progenics Pharmaceuticals Inc Earnings Release - Before Market Open Nov 07 2014
Progenics Pharmaceuticals Sets Third Quarter Financial Results Call for November 7 Oct 27 2014
Progenics Pharmaceuticals Sets Third Quarter Financial Results Call for November 7 Oct 27 2014
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 20 2014
Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress Oct 20 2014
Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress Oct 20 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK